← All compounds
peptide19 listings
Exenatide
GLP-1 Agonist (Short-Acting)
First-generation GLP-1 agonist. FDA approved.
Metabolic researchGlucose control
/ research index
The research base
Research Maturity
★★★★★
5/5 — Volume of studies
Evidence Strength
★★★★★
5/5 — Quality of evidence
Decades of clinical research. FDA approved.
/ mechanism of action
How it works
GLP-1 receptor agonist with shorter half-life than semaglutide.
/ research dosing
Common research protocols
Range
5-10 mcg, 2x daily
Frequency
Twice daily, 30-60 min before meals
Route
Subcutaneous
Cycle
Continuous
Research notes
Short-acting GLP-1 (Byetta). Start at 5mcg BID for 4 weeks, increase to 10mcg BID. Take 30-60 min before AM and PM meals.
References
FDA Byetta label
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
Strong standalone evidence.
/ side effects
What to know
Common: nausea, GI adjustment.
/ timeline
Realistic expectations
2-4 weeks
/ recommendation
Where to buy Exenatide
🏆Our pick for Exenatide
Modern Research Peptides
5mg · USA · Card / Crypto
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch comprehensive
- ✓Highest verification tier in stock
- ✓4.8★ community rating
Also solid
/ all listings
Full index, price per mg
Supplier
Trust Score
Size
Price
$/mg
Stock
Buy
FOR RESEARCH USE ONLY. Exenatide is intended for laboratory research and not for human consumption.